A new clinical trial, sponsored by the Defense and Veterans Center for Integrative Pain Management and Neurolumen LLC, has been announced to evaluate the efficacy of combined device therapies in treating chronic low back pain. Utilizing Active Neurolumen, the trial will focus on a combination of electrical stimulation, LED, and laser therapies. This study is currently listed as not yet recruiting but holds significant promise for advancing non-invasive pain management approaches.
What is this trial about?
The upcoming trial will assess the effectiveness and safety of the Active Neurolumen device compared to an inactive version. Chronic low back pain is a prevalent condition that severely impacts quality of life. This study aims to provide evidence for device-based interventions as a potential alternative to pharmacological treatments, particularly in populations such as veterans who may experience unique pain management challenges.
The study is categorized under devices and aims to combine multiple modes of action in a single intervention. This includes electrical stimulation, LED light therapy, and laser therapy. These technologies work together to potentially reduce pain and inflammation while promoting tissue healing.
How does the Active Neurolumen work?
The Active Neurolumen device integrates three therapeutic modalities: electrical stimulation to modulate nerve activity, LED therapy for cellular energy enhancement, and laser therapy targeting deeper tissues for pain relief and inflammation reduction. This combination creates an innovative, non-invasive approach designed to address chronic pain comprehensively.
The inactive Neurolumen, used as the comparator in the trial, will help establish a robust control, ensuring the observed effects can be attributed specifically to the active components.
All device-related protocols will adhere to applicable regulatory standards, including device performance and safety validations consistent with MDR and FDA guidelines.
What are the next steps?
Although the trial is currently not recruiting, interested parties in the clinical, regulatory, and quality domains should monitor updates on recruitment status, protocol developments, and preliminary findings. Researchers involved in chronic pain management, device regulation, or veterans’ health may find this trial particularly relevant.
Details regarding study timelines, enrollment criteria, and clinical endpoints will become available on the trial’s page: clinicaltrials.gov.
FAQ
- What is the primary goal of this trial?
To evaluate the efficacy of the Active Neurolumen device in reducing symptoms of chronic low back pain compared to an inactive device. - What makes this device innovative?
It combines three proven therapies—electrical stimulation, LED therapy, and laser therapy—into a single application. - Who might benefit from this study?
Patients with chronic low back pain, particularly veterans or individuals needing non-invasive methods of pain management. - Where can I find more information?
Details are available on ClinicalTrials.gov.
Key takeaways
The upcoming trial represents a significant step in advancing non-invasive, device-based treatments for chronic low back pain. As multidisciplinary modalities gain traction, this study could pave the way for novel regulatory and clinical frameworks. Stakeholders should continue to track developments for practical insights and potential implementation in healthcare settings.
Important disclaimer
This content is informational and intended for clinical, quality, and regulatory professionals. It does not constitute legal or medical advice. Always consult relevant guidelines or legal counsel for compliance obligations.